News

TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in the U.S. and Europe Los Altos, CA, June 9, 2020 – RenovoRx, an innovator in targeted cancer…

TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in U.S. and Europe Los Altos, CA, June 2, 2020 – RenovoRx, an innovator in targeted cancer therapy,…

TIGeR-PaC Phase III trial reaches first patient in Europe, with overall enrollment exceeding 20 percent worldwide Los Altos, Calif., Boston, Durham, N.C.– Jan. 13, 2020 – RenovoRx, Inc., an innovator in…

Phase III Clinical Trial for Pancreatic Cancer Patients Currently Enrolling Los Altos, CA, January 8, 2020 – RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent…

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies. Reviews how recent advances in surgery, radiation therapy, ablative options, and…

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.

Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.